Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Szafer

Showing results (51-60 of 77) with videos related to

Pageof 8
Sort By:
Human Pathology|April 18, 2017
Rituximab treatment circumvents the prognostic impact of tumor-infiltrating T-cells in follicular lymphoma patientsLuc Xerri, Sarah Huet, Jeffrey M Venstrom, et al.
The Lancet. Oncology|February 6, 2025
Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 studyMichael Wang, Wojciech Jurczak, Marek Trneny, et al.
Eclinicalmedicine|January 9, 2023
The iR<sup>2</sup> regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: A multicentre, non-randomised, open-label phase 2 studyRadhakrishnan Ramchandren, Peter Johnson, Nilanjan Ghosh, et al.
Blood|January 9, 2019
Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCLMagdalena Klanova, Laurie H Sehn, Isabelle Bence-Bruckler, et al.
Blood|February 23, 2022
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohortConstantine S Tam, John N Allan, Tanya Siddiqi, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 11, 2020
BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor PrognosisElizabeth Punnoose, Franklin V Peale, Edith Szafer-Glusman, et al.
Blood|August 14, 2020
Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphomaPier Luigi Zinzani, Ian W Flinn, Sam L S Yuen, et al.
British Journal of Cancer|September 18, 2015
PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patientsElizabeth A Punnoose, Roberta Ferraldeschi, Edith Szafer-Glusman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2021
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE StudyWilliam G Wierda, John N Allan, Tanya Siddiqi, et al.
Cell|May 11, 2020
The Allen Mouse Brain Common Coordinate Framework: A 3D Reference AtlasQuanxin Wang, Song-Lin Ding, Yang Li, et al.
Pageof 8

Showing results (51-60 of 77) with videos related to

Sort By:
Pageof 8
Human Pathology|April 18, 2017
Rituximab treatment circumvents the prognostic impact of tumor-infiltrating T-cells in follicular lymphoma patientsLuc Xerri, Sarah Huet, Jeffrey M Venstrom, et al.
The Lancet. Oncology|February 6, 2025
Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 studyMichael Wang, Wojciech Jurczak, Marek Trneny, et al.
Eclinicalmedicine|January 9, 2023
The iR<sup>2</sup> regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: A multicentre, non-randomised, open-label phase 2 studyRadhakrishnan Ramchandren, Peter Johnson, Nilanjan Ghosh, et al.
Blood|January 9, 2019
Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCLMagdalena Klanova, Laurie H Sehn, Isabelle Bence-Bruckler, et al.
Blood|February 23, 2022
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohortConstantine S Tam, John N Allan, Tanya Siddiqi, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 11, 2020
BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor PrognosisElizabeth Punnoose, Franklin V Peale, Edith Szafer-Glusman, et al.
Blood|August 14, 2020
Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphomaPier Luigi Zinzani, Ian W Flinn, Sam L S Yuen, et al.
British Journal of Cancer|September 18, 2015
PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patientsElizabeth A Punnoose, Roberta Ferraldeschi, Edith Szafer-Glusman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2021
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE StudyWilliam G Wierda, John N Allan, Tanya Siddiqi, et al.
Cell|May 11, 2020
The Allen Mouse Brain Common Coordinate Framework: A 3D Reference AtlasQuanxin Wang, Song-Lin Ding, Yang Li, et al.
Pageof 8